Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Story Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostReported by Chris Markoch. Publication Date: 2/5/2026. 
Key Takeaways - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion, and adjusted earnings per share (EPS) came in at $0.69 versus estimates of $0.57. Highlighting the quarter was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. PFE stock closed up about 4% on Feb. 4 as analysts and investors digested the report. Elon's Next Market Move Could Send Silver Soaring
Every industry Elon Musk touches explodes—from Tesla to SpaceX to AI.
And now, whispers are growing that his next move could be in silver.
Why? Because silver is the lifeblood of EVs, solar panels, and AI tech. Smart money is already watching silver closely. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a meaningful clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. One forecast shows the global GLP-1 market growing from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate of roughly 9.7%. That is why billions of dollars are flowing into the industry as companies try to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET‑097i. Results from the Phase 2b VESPER‑3 study showed the trial met its primary endpoint with a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after switching from weekly to monthly dosing, with no plateau observed by week 28. The Growth Driver Investors May Be Missing After the report, much of the market reaction was attributed to the positive GLP-1 data. That may be true, but investors should recognize that GLP-1 excitement can be a near-term sugar high. While Pfizer's obesity program shows promise, it will take time for sales to meaningfully affect the company's financials. The GLP-1 trade is also expanding — and established competitors such as Eli Lilly & Co. (NYSE: LLY) are not going to cede leadership easily. There are, however, additional reasons to be bullish on PFE — most notably its oncology portfolio. Business Research Insights estimates the global oncology drugs market at roughly $264.92 billion in 2026, projected to climb to $648.08 billion by 2035, reflecting a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its development portfolio — translating into multiple opportunities to capture market share. The company's pipeline was significantly strengthened by its acquisition of Seagen in 2023, which added expertise particularly in antibody-drug conjugates (ADCs). Pfizer's late-stage programs include Vepdegestrant, a next-generation targeted protein degrader (PROTAC), paired with atirmociclib, a selective CDK4 inhibitor, both aimed at ER+/HER2‑ metastatic breast cancer. Two other late-stage candidates include: - Sigvotatug vedotin, an ADC in Phase 3 testing (e.g., Be6A LUNG‑01) against metastatic non-small cell lung cancer, leveraging Seagen's ADC expertise.
- Sasanlimab, a therapy targeting bladder cancer; and a bispecific PD‑1xVEGF agent (PF‑4404) that is being evaluated in combination with Padcev to treat urothelial cancer, positioning these programs as potential blockbusters amid oncology growth.
Pfizer could bring multiple new drugs to market over the next five to 10 years. That outlook is reinforced by the company's growing commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships such as Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. The company says tools like OncoScout have sped target identification by at least 50%. Internally, platforms such as "Charlie" are used for data mining, prediction and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing workflows. These efforts were important in Pfizer's rapid development of Paxlovid and support upcoming 2026 catalysts in oncology and obesity. The company is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to improve productivity by an estimated 35% to 45% by refining preclinical decisions and trials, making it a core competitive advantage rather than optional hype. Pfizer's early and broad adoption of these tools should benefit investors over the medium and long term.
| 
